3,486 results on '"Welte Tobias"'
Search Results
152. Plasma levels of alpha1-antitrypsin-derived C-terminal peptides in PiMM and PiZZ COPD patients
153. Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19
154. Midregional pro atrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all- cause mortality in early COPD – Results from COSYCONET
155. Alveolar Vascular Remodeling in Nonspecific Interstitial Pneumonia: Replacement of Normal Lung Capillaries with COL15A1-Positive Endothelial Cells
156. REAL-WORLD OUTCOMES WITH MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ACCORDING TO SMOKING HISTORY AND COPD STATUS AT ENROLLMENT: REALITI-A POST HOC ANALYSIS
157. The implementation of a pretomanid-based treatment regimen for multidrug-resistant tuberculosis
158. Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
159. Macrophages and their Stress Response – Environmental Triggers of Respiratory Diseases
160. Clinical factors linked to the type of respiratory medication in COPD: Results from COSYCONET
161. The bronchiectasis exacerbation definition in a real-world setting: data from the EMBARC registry
162. The microbiology of bronchiectasis in Europe: Data from the European Bronchiectasis Registry (EMBARC)
163. Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study
164. Effects of patient serum containing different profiles and magnitudes of inflammatory markers on human microvascular lung endothelial and bronchial epithelial cells
165. Sputum colour assessment and clinical outcomes in bronchiectasis: data from the EMBARC Registry
166. Pseudomonas aeruginosa eradication in patients with bronchiectasis: data from the EMBARC registry
167. Late Breaking Abstract - Diversity of endothelial cells in restrictive allograft syndrome
168. Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone
169. Treatment with low-molecular-weight heparin negatively effects lung cancer patient survival
170. Vilobelimab’s effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
171. “Super Survivor” after Lung Transplantation – Protective Role of Macrophages?
172. Morphomolecular analysis of the capillary network in alveolar capillary dysplasia
173. Alpha-1 antitrypsin deficiency genotypes in a large international cohort study of bronchiectasis (EMBARC BRIDGE)
174. Convergent validity of the Bronchiectasis Impact Measure: data from the EMBARC-BRIDGE study
175. Validation of the Rose Criteria for COPD-Bronchiectasis Overlap: Data from the European Bronchiectasis Registry (EMBARC)
176. Neutrophil metabolomics in bronchiectasis: data from the EMBARC BRIDGE study
177. Blood eosinophils, inhaled corticosteroids and exacerbations in bronchiectasis: Data from the EMBARC registry
178. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus
179. Steiniger Weg zur personalisierten Therapie
180. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
181. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19
182. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
183. Left ventricular volume and wall stress are linked to lung function impairment in COPD
184. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial
185. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling
186. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
187. Adenoviral vector-mediated GM-CSF gene transfer improves anti-mycobacterial immunity in mice – role of regulatory T cells
188. Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD
189. The revised GOLD 2017 COPD categorization in relation to comorbidities
190. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
191. Influenza – jeder kennt die „Grippe“ und doch wird sie immer noch unterschätzt
192. M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections
193. Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
194. Circulating hyaluronic acid signature in CAP and ARDS – the role of pneumolysin in hyaluronic acid shedding
195. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy
196. Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease – a lesson learned from cystic fibrosis
197. Pleural infection caused by Mycobacterium kansasii in a patient after lung transplantation
198. Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
199. S100A9 is indispensable for survival of pneumococcal pneumonia in mice
200. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.